Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. on May 22, 2017. The registrant is an emerging growth company incorporated in Nevada. The report details a strategic operational restructuring plan implemented on the filing date to streamline operations and reduce cash burn.
Key Financial Metrics and Restructuring Costs
The filing does not provide historical revenue, profit, or cash flow figures for the period. Instead, it outlines specific projected costs associated with the workforce reduction:
- Total Restructuring Expense: Approximately $1.0 million expected to be recorded in 2017.
- Cash Expenditures: Approximately $0.8 million, with the majority expensed and paid in Q2 2017 and the remainder in Q3 2017.
- Non-Cash Expenses: Approximately $0.2 million in one-time stock-based compensation, expected to be expensed in Q3 2017.
- Workforce Reduction: Approximately 25% of the workforce.
Material Changes
The primary material change is the implementation of a cost-cutting plan involving a 25% reduction in staff. This action is intended to lower operating expenses and reduce the company's cash burn rate. The company is offering severance packages including cash payments, restricted stock units, outplacement services, and health care premium payments, contingent upon the execution of separation agreements.
Outlook, Risks, and Management Commentary
Management expects to complete the restructuring actions by the end of the third quarter of 2017. The filing includes extensive forward-looking statements regarding the timing of expense reductions and anticipated cost savings. Key risks identified include:
- Inability to obtain adequate financing to fund operations and technology development.
- Delays in product development and commercialization of human exoskeletons.
- Failure to achieve broad market acceptance or effective marketing.
- Adverse results in clinical studies or failure to obtain regulatory approvals.
- Failure to maintain patent protection.
Actual results may differ materially from projections due to these uncertainties.
Investor Verification Checklist
- Verify the actual cash burn rate reduction post-restructuring in subsequent quarterly reports.
- Confirm the timing and total amount of the $1.0 million restructuring charge in the Q2 and Q3 2017 financial statements.
- Monitor the company's ability to secure financing as highlighted in the risk factors.
- Review progress on regulatory approvals and clinical study results for medical device products.
- Check for any additional charges or costs not currently contemplated in the restructuring plan.